Patients and treatment characteristics
| . | All patients (n = 159) . | Chemotherapy group (n = 105) . | HSCT group (n = 54) . | P . |
|---|---|---|---|---|
| Patient and disease related characteristics | ||||
| Sex | ||||
| Female, n (%) | 80 (50.3) | 57 (54.3) | 23 (42.6) | .18 |
| Male, n (%) | 79 (49.7) | 48 (45.7) | 31 (57.4) | |
| Initial diagnosis | ||||
| ALL, n (%) | 130 (81.8) | 96 (91.4) | 34 (63) | < .0001 |
| AML, n (%) | 29 (18.2) | 9 (8.6) | 20 (37) | |
| Age at diagnosis, y, mean ± SEM | 8.33 ± 0.38 | 8.03 ± 0.44 | 8.9 ± 0.72 | .30 |
| Age at HSCT, y, mean ± SEM | 10.4 ± 0.74 | NA | ||
| Relapse, n (%) | 29(18.2) | 4 (3.8) | 25 (46.3) | <.0001 |
| Follow-up, y, mean ± SEM | 14.66 ± 0.44 | 14.83 ± 0.54 | 14.34 ± 0.74 | .60 |
| Age at DXA scan, y, mean ± SEM | 23.05 ± 0.38 | 22.99 ± 0.47 | 23.17 ± 0.66 | .82 |
| Treatment modalities | ||||
| Corticotherapy | ||||
| Yes, n (%) | 137 (86.2) | 96 (91.4) | 41 (75.9) | .007 |
| Prednisone, n (%) | 137 (86.2) | 96 (91.4) | 41 (75.9) | .007 |
| Dexamethasone, n (%) | 95 (59.7) | 70 (66.7) | 25 (46.3) | .01 |
| Mean ± SD total dose of steroids, mg/m2* | 4534 ± 229 | 4488 ± 224 | 4622 ± 517 | .81 |
| Cranial radiation, n (%) | 30 (18.9) | 28 (26.7) | 2 (3.7) | <.0001 |
| TBI, n (%) | 38 (70.4) | NA | ||
| Type of graft | ||||
| Allograft, n (%) | 36 (66.7) | NA | ||
| Autograft, n (%) | 18 (33.3) | |||
| Posttransplantation steroid therapy | ||||
| Yes, n (%) | 23 (42.6) | NA | ||
| Mean ± SD dose, mg/m2 | 444 ± 111 | NA | ||
| Treatment-related complications | ||||
| GVH disease, n (%) | 23 (42.6) | NA | ||
| Acute GVHD, n (%) | 20 (37.1) | |||
| Chronic GVHD, n (%) | 13 (24.1) | |||
| Significant GVHD, n (%)† | 17 (31.5) | |||
| Treatment for GVHD, n (%) | 19 (35.2) | |||
| Hypogonadism | ||||
| Yes, n (%) | 30 (18.9) | 2 (1.9) | 28 (51.9) | <.0001 |
| Compensated hypogonadism, n (%) | 18 (11.3) | 1 (0.9) | 17 (31.5) | <.999 |
| Uncompensated hypogonadism, n (%) | 12 (7.5) | 1 (0.9) | 11 (20.4) | |
| GHD, n (%) | 6 (3.8) | 1 (1) | 5 (9.3) | .02 |
| . | All patients (n = 159) . | Chemotherapy group (n = 105) . | HSCT group (n = 54) . | P . |
|---|---|---|---|---|
| Patient and disease related characteristics | ||||
| Sex | ||||
| Female, n (%) | 80 (50.3) | 57 (54.3) | 23 (42.6) | .18 |
| Male, n (%) | 79 (49.7) | 48 (45.7) | 31 (57.4) | |
| Initial diagnosis | ||||
| ALL, n (%) | 130 (81.8) | 96 (91.4) | 34 (63) | < .0001 |
| AML, n (%) | 29 (18.2) | 9 (8.6) | 20 (37) | |
| Age at diagnosis, y, mean ± SEM | 8.33 ± 0.38 | 8.03 ± 0.44 | 8.9 ± 0.72 | .30 |
| Age at HSCT, y, mean ± SEM | 10.4 ± 0.74 | NA | ||
| Relapse, n (%) | 29(18.2) | 4 (3.8) | 25 (46.3) | <.0001 |
| Follow-up, y, mean ± SEM | 14.66 ± 0.44 | 14.83 ± 0.54 | 14.34 ± 0.74 | .60 |
| Age at DXA scan, y, mean ± SEM | 23.05 ± 0.38 | 22.99 ± 0.47 | 23.17 ± 0.66 | .82 |
| Treatment modalities | ||||
| Corticotherapy | ||||
| Yes, n (%) | 137 (86.2) | 96 (91.4) | 41 (75.9) | .007 |
| Prednisone, n (%) | 137 (86.2) | 96 (91.4) | 41 (75.9) | .007 |
| Dexamethasone, n (%) | 95 (59.7) | 70 (66.7) | 25 (46.3) | .01 |
| Mean ± SD total dose of steroids, mg/m2* | 4534 ± 229 | 4488 ± 224 | 4622 ± 517 | .81 |
| Cranial radiation, n (%) | 30 (18.9) | 28 (26.7) | 2 (3.7) | <.0001 |
| TBI, n (%) | 38 (70.4) | NA | ||
| Type of graft | ||||
| Allograft, n (%) | 36 (66.7) | NA | ||
| Autograft, n (%) | 18 (33.3) | |||
| Posttransplantation steroid therapy | ||||
| Yes, n (%) | 23 (42.6) | NA | ||
| Mean ± SD dose, mg/m2 | 444 ± 111 | NA | ||
| Treatment-related complications | ||||
| GVH disease, n (%) | 23 (42.6) | NA | ||
| Acute GVHD, n (%) | 20 (37.1) | |||
| Chronic GVHD, n (%) | 13 (24.1) | |||
| Significant GVHD, n (%)† | 17 (31.5) | |||
| Treatment for GVHD, n (%) | 19 (35.2) | |||
| Hypogonadism | ||||
| Yes, n (%) | 30 (18.9) | 2 (1.9) | 28 (51.9) | <.0001 |
| Compensated hypogonadism, n (%) | 18 (11.3) | 1 (0.9) | 17 (31.5) | <.999 |
| Uncompensated hypogonadism, n (%) | 12 (7.5) | 1 (0.9) | 11 (20.4) | |
| GHD, n (%) | 6 (3.8) | 1 (1) | 5 (9.3) | .02 |